Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01294280 · ClinicalTrials.gov registry record
Biomarkers in Predicting Response in Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy
A clinical trial, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- 241
- Enrollment target
NCT01294280 is a clinical trial that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 241 participants.
The verdict
NCT01294280 has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- 241 participants
- Enrollment target
Study Summary
This research trial studies prognostic and predictive markers in patients with early stage non-small cell lung cancer receiving chemotherapy. Prognostic markers are patient or tumor factors that predict patient survival independent of treatment. Predictive markers are factors that may influence and predict the outcome of treatment in terms of either response or survival benefit. Collecting and storing samples of tissue from patients with cancer to study in the laboratory may help doctors learn more about cancer and identify biomarkers related to cancer.
Interventions
- OTHER Laboratory Biomarker Analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 241 participants |
| Start Date | 2008-07 |
| Est. Completion | 2016-02-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01294280
The ClinicalTrials.gov registry entry for NCT01294280 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 241 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Laboratory Biomarker Analysis is the first listed.
NCT01294280 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01294280 about?
NCT01294280 is a clinical study titled "Biomarkers in Predicting Response in Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy". This research trial studies prognostic and predictive markers in patients with early stage non-small cell lung cancer receiving chemotherapy. Prognostic markers are patient or tumor factors that predict patient survival independent of treatment. Predictive markers are factors that may influence and ...
What is the current status of trial NCT01294280?
This trial is currently completed. The enrollment target is 241 participants. The study started on 2008-07. Estimated completion is 2016-02-02.
What interventions are being tested in trial NCT01294280?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER).
Who is sponsoring clinical trial NCT01294280?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.